US1628181083 - Common Stock
CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biotechnology...
CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (Nasdaq: CMPI) (“Checkmate”), a clinical stage biopharmaceutical...
/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...
/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...
/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...
Regeneron and Checkmate sign a definitive agreement that will see Regeneron acquire Checkmate for $250 million
/PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Checkmate...
/PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Arqit Quantum (ARQQ) stock is slipping on Tuesday after former employees make allegations about the company's capabilities.
Checkmate Pharmaceuticals (CMPI) stock is rocketing higher on Tuesday following news that Regeneron Pharmaceuticals (REGN) is acquiring it.
/PRNewswire/ -- Ademi LLP is investigating Checkmate (NASDAQ:CMPI) for possible breaches of fiduciary duty and other violations of law in its transaction with...
Proposed ~$250 million all-cash acquisition strengthens Regeneron’s portfolio of diverse and combinable immuno-oncology candidates Lead...
/PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI), a clinical stage biopharmaceutical company...
CAMBRIDGE, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biotechnology...
Alan Bash, experienced biopharmaceutical executive, appointed President and CEO Clinical trials with vidutolimod (CMP-001) in melanoma, head and neck...
CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biotechnology...
CAMBRIDGE, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical...